Standout Papers

ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well T... 2002 2026 2010 2018 641
  1. ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I Trial (2002)
    Malcolm Ranson, Lisa A. Hammond et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 7 from Science/Nature 95 standout
Sub-graph 1 of 19

Citing Papers

Small RNAs are modified with N-glycans and displayed on the surface of living cells
2021 StandoutNobel
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
2 intermediate papers

Works of Philip I. Murray being referenced

EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors
2012
Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer
2007

Author Peers

Author Last Decade Papers Cites
Philip I. Murray 3564 1273 2134 1920 254 9.2k
Justine R. Smith 3168 1084 646 919 261 7.7k
José S. Pulido 5182 474 1730 2556 334 10.2k
Daniel M. Albert 7355 608 4096 4792 474 14.8k
Robert I. Fox 732 3414 1523 1668 136 12.4k
Robert M. Verdijk 1550 402 993 1202 192 4.6k
Lai Wei 687 365 1727 4838 176 10.6k
Robert B. Nussenblatt 15626 5015 1513 2722 428 24.5k
Christophe Combadière 939 437 3734 2574 167 12.8k
Patrice Debré 481 675 2050 2502 385 18.0k
Ali H. Hajeer 336 2008 708 817 217 7.4k

All Works

Loading papers...

Rankless by CCL
2026